and NABP to conduct inspections of all nonresident pharmacies includ- ing those believed to be delivering compounded drugs into the state. Ongo- ing surveys are focused on inspecting all nonresident pharmacies shipping into the state of Iowa for the purpose of facilitating licensure and to confirm that all pharmacies provid- ing product and services
to patients in Iowa, in particular those entities engaging in sterile or other drug compounding, are doing so in a safe and legal manner.
with the Iowa Board, since mid-December, NABP surveyors have completed inspections of 100 pharmacies in nine states. Inspections are ongoing across the nation and as such are not consigned to any one state. On average, NABP surveyors complete 15 to 20 inspections a week, with reports submitted directly to the Iowa Board.
of pharmacy in each state, and in several states board inspectors have accompa- nied NABP surveyors on inspections.
Aggregate data reports with relevant survey findings, along with Surveyor Scoring Reports are disseminated to the Iowa Board of Pharmacy on a weekly basis. Initial results of the inspections include a wide range of observations on the entities inspected
to date. For example, when visiting some sites, surveyors discovered that the facilities ceased compounding activity in late 2012. In a few instances, the address of the company was no longer valid, and it must
be determined whether
the entity moved, or is no longer in operation, and whether they notified the home or nonresident states in which they hold licenses. Some facilities had voluntarily surrendered their Iowa license prior
to the date of inspection but their products are still being used in Iowa, and some indicated they main- tained Iowa licensure only as part of the company’s contingency planning,
and were not distributing or dispensing drugs into the state. In those cases an inspection is done because distribution to Iowa can occur at any time. Other initial observations for the Iowa Board include documentation that some pharmacies are distributing sterile or other compounded drugs for office use, and some are using central fill processing for sterile and non-sterile compounded drugs.
Quoted from the National Board of Pharmacy May 2013 Newsletter